Subscribe
shutterstock_1857404794_michael_vi
Michael Vi / Shutterstock.com
21 January 2021Big PharmaMuireann Bolger

Illumina prevails against BGI at English High Court

Illumina has secured a victory in its patent dispute with Chinese genome sequencing company BGI at the English High Court, which ruled that four of its patents had been infringed.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Illumina and Ariosa settle DNA patent dispute
27 May 2021   Illumina and Roche-owned Ariosa Diagnostics filed a joint stipulation asking the US Supreme Court to dismiss a case concerning the eligibility of Illumina’s DNA testing patents.
Asia
BGI wins $333m in DNA patent suit with Illumina
9 May 2022   Illumina has been ordered to pay more than $333 million to Chinese sequencing company MGI—a subsidiary of BGI Group formally known as Complete Genomics—following a jury ruling that Illumina infringed two of its DNA-sequencing patents.
Big Pharma
EU blocks $7.1bn takeover of cancer detection company
8 September 2022   Illumina bid would have “stifled innovation” | EU said Illumina was the "unrivalled supplier” of next-generation sequencing systems for genetic and genomic analysis.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
Illumina and Ariosa settle DNA patent dispute
27 May 2021   Illumina and Roche-owned Ariosa Diagnostics filed a joint stipulation asking the US Supreme Court to dismiss a case concerning the eligibility of Illumina’s DNA testing patents.
Asia
BGI wins $333m in DNA patent suit with Illumina
9 May 2022   Illumina has been ordered to pay more than $333 million to Chinese sequencing company MGI—a subsidiary of BGI Group formally known as Complete Genomics—following a jury ruling that Illumina infringed two of its DNA-sequencing patents.
Big Pharma
EU blocks $7.1bn takeover of cancer detection company
8 September 2022   Illumina bid would have “stifled innovation” | EU said Illumina was the "unrivalled supplier” of next-generation sequencing systems for genetic and genomic analysis.

More on this story

Big Pharma
Illumina and Ariosa settle DNA patent dispute
27 May 2021   Illumina and Roche-owned Ariosa Diagnostics filed a joint stipulation asking the US Supreme Court to dismiss a case concerning the eligibility of Illumina’s DNA testing patents.
Asia
BGI wins $333m in DNA patent suit with Illumina
9 May 2022   Illumina has been ordered to pay more than $333 million to Chinese sequencing company MGI—a subsidiary of BGI Group formally known as Complete Genomics—following a jury ruling that Illumina infringed two of its DNA-sequencing patents.
Big Pharma
EU blocks $7.1bn takeover of cancer detection company
8 September 2022   Illumina bid would have “stifled innovation” | EU said Illumina was the "unrivalled supplier” of next-generation sequencing systems for genetic and genomic analysis.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York